

Takahiro Miyazu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12057590/publications.pdf>

Version: 2024-02-01

17
papers

96
citations

1478505

6
h-index

1474206

9
g-index

22
all docs

22
docs citations

22
times ranked

79
citing authors

#	ARTICLE	IF	CITATIONS
1	C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. <i>Scientific Reports</i> , 2021, 11, 12431.	3.3	15
2	Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 1509.	2.4	13
3	Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. <i>BMC Gastroenterology</i> , 2020, 20, 114.	2.0	10
4	Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1729-1739.	2.2	9
5	Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3984-3992.	2.3	7
6	Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00289.	2.5	7
7	Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation. <i>Scientific Reports</i> , 2020, 10, 21353.	3.3	6
8	Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2021, 16, e0254548.	2.5	5
9	Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. <i>Scientific Reports</i> , 2021, 11, 16205.	3.3	5
10	Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2661-2670.	2.2	5
11	Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e3-e4.	1.9	4
12	Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report. <i>World Journal of Gastroenterology</i> , 2020, 26, 7263-7271.	3.3	4
13	Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis. <i>Scientific Reports</i> , 2021, 11, 13676.	3.3	3
14	A Rare Lesion at the Ileostomy Site of a Patient With Intestinal Behçet's Disease. <i>Gastroenterology</i> , 2020, 159, e14-e15.	1.3	2
15	Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. <i>Gastroenterology Report</i> , 2022, 10, .	1.3	1
16	Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease. <i>PLoS ONE</i> , 2021, 16, e0250658.	2.5	0
17	Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. <i>Immuno</i> , 2021, 1, 360-368.	1.5	0